DekaBank Deutsche Girozentrale’s Denali Therapeutics DNLI Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.13M	Hold	59,800	–	–	﹤0.01%	768
2026 Q1	$1.15M	Hold	59,800	–	–	﹤0.01%	768
2025 Q4	$1.35M	Hold	59,800	–	–	﹤0.01%	827
2025 Q3	$864K	Hold	59,800	–	–	﹤0.01%	900
2025 Q2	$841K	Sell	59,800 -4,410	-7%	-$62.1K	﹤0.01%	898
2025 Q1	$935K	Buy	64,210 +4,410	+7%	+$84.5K	﹤0.01%	864
2024 Q4	$1.22M	Hold	59,800	–	–	﹤0.01%	839
2024 Q3	$1.75M	Hold	59,800	–	–	﹤0.01%	785
2024 Q2	$1.37M	Sell	59,800 -4,410	-7%	-$84.7K	﹤0.01%	828
2024 Q1	$1.32M	Hold	64,210	–	–	﹤0.01%	824
2023 Q4	$1.42M	Hold	64,210	–	–	﹤0.01%	838
2023 Q3	$1.35M	Buy	64,210 +4,410	+7%	+$112K	﹤0.01%	820
2023 Q2	$1.75M	Hold	59,800	–	–	﹤0.01%	779
2023 Q1	$1.32M	Hold	59,800	–	–	﹤0.01%	814
2022 Q4	$1.67M	Hold	59,800	–	–	﹤0.01%	760
2022 Q3	$1.74M	Hold	59,800	–	–	0.01%	739
2022 Q2	$1.71M	Hold	59,800	–	–	0.01%	754
2022 Q1	$1.94M	Buy	59,800 +5,400	+10%	+$186K	﹤0.01%	760
2021 Q4	$2.37M	Buy	54,400 +1,500	+3%	+$71.1K	0.01%	730
2021 Q3	$2.61M	Hold	52,900	–	–	0.01%	669
2021 Q2	$4.03M	Buy	52,900 +15,000	+40%	+$928K	0.01%	572
2021 Q1	$2.08M	Hold	37,900	–	–	0.01%	688
2020 Q4	$3.22M	Buy	37,900 +2,100	+6%	+$127K	0.01%	551
2020 Q3	$1.28M	Buy	+35,800	New	+$1.08M	0.01%	696
2019 Q3	–	Sell	-74,000	Closed	-$1.52M	–	1025
2019 Q2	$1.52M	Buy	+74,000	New	+$1.66M	0.01%	693

Other funds holding DNLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

DekaBank Deutsche Girozentrale's DNLI Position: Q2 2026 in Review

DekaBank Deutsche Girozentrale held its Denali Therapeutics (DNLI) position steady in Q2 2026 at 59,800 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #768.

DekaBank Deutsche Girozentrale first reported a position in DNLI in Q2 2019 and has held it in 25 quarters since. The position peaked at $4.03M in Q2 2021. 122 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

DekaBank Deutsche Girozentrale held 59,800 shares of Denali Therapeutics worth $1.13M as of Q2 2026.
DekaBank Deutsche Girozentrale left its Denali Therapeutics share count unchanged in Q2 2026.
Denali Therapeutics made up ﹤0.01% of DekaBank Deutsche Girozentrale's portfolio in Q2 2026, its #768 holding.
DekaBank Deutsche Girozentrale first reported a position in Denali Therapeutics in Q2 2019 and has held it in 25 quarters since.
DekaBank Deutsche Girozentrale's Denali Therapeutics position peaked at $4.03M in Q2 2021.
122 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2026, filed 5 Aug 2026.